Friday, May 07, 2021 7:43:33 PM
Biosect,
I think that I completely understand your point of view...if I can dumb it down for me to digest it is that the ‘enforcement’ of failing to provide investors with material information in a timely manner is the court system through law suits. Is this reasonably accurate?
Allow me ask a few questions that come at this from a different angle please. I do not know many of these answers and am legitimately asking although sometimes adding color.
Should a lawsuit be brought and won as to the question of failure to deliver in good faith, does LP carry any personal liability or is it solely the entity known as NWBO? How about if she were to strike financial deals like say an $11M loan with full knowledge of materially negative information that could easily bankrupt the company?
Would a response from FDA indicating that they will not accept the SAP as submitted or as they like to do sometimes ‘recommend’ that you run another trial be material? If Dr. Liau were to have a financial stake in any of these outcomes could she be liable for having this knowledge and continuing to promote DCVAX and/or the p3 trial design as viable? How about if she were to continue to treat patients with this knowledge instead of offering them approved alternatives and/or available research options?
Can a patient with a brain tumor provide reasonable consent to a therapy that is offered by someone or someplace that has a financial stake in that therapy if any of the above scenarios are true? Would an IRB let them? How about the attorney for that institution? Does NWBO have an obligation to update its investigators of any negative update about a research product immediately?
I can actually keep going on but I think these will suffice. The answers all come back to the ‘legality’ of withholding negative material information which I consider personal restitution to be similar enough to warrant no competent lawyer on Earth would allow. These families can go after individuals BTW. This I know.
I think that I completely understand your point of view...if I can dumb it down for me to digest it is that the ‘enforcement’ of failing to provide investors with material information in a timely manner is the court system through law suits. Is this reasonably accurate?
Allow me ask a few questions that come at this from a different angle please. I do not know many of these answers and am legitimately asking although sometimes adding color.
Should a lawsuit be brought and won as to the question of failure to deliver in good faith, does LP carry any personal liability or is it solely the entity known as NWBO? How about if she were to strike financial deals like say an $11M loan with full knowledge of materially negative information that could easily bankrupt the company?
Would a response from FDA indicating that they will not accept the SAP as submitted or as they like to do sometimes ‘recommend’ that you run another trial be material? If Dr. Liau were to have a financial stake in any of these outcomes could she be liable for having this knowledge and continuing to promote DCVAX and/or the p3 trial design as viable? How about if she were to continue to treat patients with this knowledge instead of offering them approved alternatives and/or available research options?
Can a patient with a brain tumor provide reasonable consent to a therapy that is offered by someone or someplace that has a financial stake in that therapy if any of the above scenarios are true? Would an IRB let them? How about the attorney for that institution? Does NWBO have an obligation to update its investigators of any negative update about a research product immediately?
I can actually keep going on but I think these will suffice. The answers all come back to the ‘legality’ of withholding negative material information which I consider personal restitution to be similar enough to warrant no competent lawyer on Earth would allow. These families can go after individuals BTW. This I know.
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
